Dr. Robert Alan Figlin, MD

Dr. Figlin practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Figlin's NPI, 1780609966, was assigned on July 12, 2006. Dr. Figlin graduated from MCP-Hahnemann College of Medicine in 1976. Dr. Figlin holds California license G35300.

Dr. Figlin's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Figlin's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Figlin practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Figlin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Figlin is board certified in internal medicine by the American Board of Internal Medicine. Dr. Figlin is licensed in California.

Dmand AI lists lung cancer among the conditions Dr. Figlin treats.

CMS data shows 166 Medicare services from Dr. Figlin across 2 procedure codes in 2024, for 59 Medicare patients. Medicare paid $11,655 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Figlin in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have cancer, and 75% have high blood pressure. 20% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Figlin's median patient age at 54, with 65% women.

In 2024, Dr. Figlin wrote 83 Medicare Part D claims. 22% of them were for generic drugs. They cover 4 drugs, with $1,641,798 in total drug cost. In 2023, CMS named 76 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Figlin for performance year 2024, reported as part of a group. Dr. Figlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 200 papers to Dr. Figlin, published from 2003 to 2023. 2014 was the busiest year, with 6. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Antineoplastic Agents. Dr. Figlin has published most often in J Clin Oncol. Dr. Figlin's most frequent co-authors are Arie Belldegrun, MD, Robert J. Motzer, MD and Thomas Edgar Hutson, DO, PharmD.

Dmand AI links Dr. Figlin to 10 clinical trials, 3 of them phase 1 studies. Conditions studied include Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms and Carcinoma, Bronchogenic. Jonsson Comprehensive Cancer Center sponsors the most, 5.

CMS Open Payments shows 161 general payments to Dr. Figlin from 13 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 79% of the total. 4DMedical USA Inc paid the most, $108,486. It also lists 4 research payments totaling $6,124 in 2016.

Dmand AI lists 5 awards for Dr. Figlin, most recently America's Top Doctors in 2014.

Dr. Figlin graduated from MCP-Hahnemann College of Medicine in 1976. Dr. Figlin is a member of ASCO.

Dr. Figlin is in network with 6 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.